CKD-516 is under clinical development by Chong Kun Dang Pharmaceutical and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect CKD-516’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their CKD-516 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

CKD-516 overview

CKD-516 (NOV-120401) is under development for the treatment of advanced solid tumors and colorectal cancer, pancreatic cancer, cholangiocarcinoma, stomach cancer and esophageal cancer. It is a new chemical entity (NCE) which is administered intravenously and orally. The drug candidate is a benzophenone derivative and water soluble valine prodrug of the tubulin binding agent S516. It acts as vascular disrupting agent (VDA), based on tubulin polymerization inhibition.

Chong Kun Dang Pharmaceutical overview

Chong Kun Dang Pharmaceutical (CKD Pharma), an affiliate of Chong Kun Dang, manufactures, distributes, imports and exports prescription drugs, OTC drugs, health supplements and consumer health products. The company works following therapeutic areas such as oncology, neurology and immunology and others. Its product portfolio includes prescription products for the entire segment and therapeutic classes; vitamins; shampoos; hair colors; aerosols; mat vaporizers and mosquito coils; and others. The company’s Chong Kun Dang Research Institute is characterized by three independent laboratories, namely, The New Drug Discovery Labs; The Technology Development Labs; and the Bio Research Labs. It has manufacturing facility in Cheonan City, South Korea. CKD Pharma is headquartered in Seoul, South Korea.

Quick View CKD-516 LOA Data

Report Segments
  • Innovator
Drug Name
  • CKD-516
Administration Pathway
  • Intravenous
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.